title: [Economic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosis].
abstract: OBJECTIVE
  Invasive aspergillosis is an infection with high incidence and mortality. Voriconazole is a new antifungal agent that presents a high efficacy against Aspergillus. The aim of this evaluation was to carry out a pharmacoeconomic analysis of the use of voriconazole versus amphotericin B deoxycholate in the treatment of invasive aspergillosis in Spain.
  
  
  METHODS
  A cost-effectiveness analysis has been performed by building a decision analytical model. Effectiveness data, probabilities of the different branches of the decision tree and consumption of healthcare resources were obtained from a clinical trial that compared voriconazole versus amphotericin B in the treatment of invasive aspergillosis and from a local expert panel in order to incorporate the model in the daily medical practice in our country. Only direct medical costs were included in the model (drug acquisition, length of hospital stay, analytical tests and treatment of therapeutic failures). The perspective chosen for this analysis was hospital assistance and the time horizon selected was 12 weeks, the maximum time that patients were followed up in the referenced clinical trial.
  
  
  RESULTS
  Therapeutic success was reached in 52.8% of patients treated with voriconazole and in 31.6% of the group treated with amphotericin B. The cost of treating a patient with voriconazole or amphotericin B was of 56,296 and 56,382 Euros respectively, while the cost/effectiveness ratio was of 106,621 and 178,424 Euros. The incremental analysis performed shows how the use of voriconazole versus amphotericin B produces a healthcare resources saving of 406 Euros per patient.
  
  
  CONCLUSIONS
  Voriconazole is more efficient than amphotericin B deoxycholate in the treatment of invasive aspergillosis, (thus) resulting in healthcare resources saving due to better clinical results with lower associated costs.
authors.affiliation: Servicio de Farmacia, Hospital del Mar, Barcelona. sgrau@imas.imim.es
authors.forename: S
authors.initials: S
authors.lastname: Grau Cerrato
authors.forename: J
authors.initials: J
authors.lastname: Mateu-de Antonio
authors.forename: J
authors.initials: J
authors.lastname: Soto Alvarez
authors.forename: M A
authors.initials: MA
authors.lastname: Muñoz Jareño
authors.forename: E
authors.initials: E
authors.lastname: Salas Sánchez
authors.forename: M
authors.initials: M
authors.lastname: Marín-Casino
authors.forename: C
authors.initials: C
authors.lastname: Rubio Terrés
mesh_terms: D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole
chemical_list: D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole